MedPath

Cat-PAD Follow on Study

Completed
Conditions
Cat Allergy
Rhinoconjunctivitis
Registration Number
NCT01272323
Lead Sponsor
Circassia Limited
Brief Summary

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.

The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to cat dander in the EEC among subjects who completed all dosing visits in study CP005 approximately one year after the start of treatment.

Detailed Description

Subjects who completed all dosing visits and the post treatment challenge (PTC) in study CP005 will be invited to attend the Screening Visit for CP005A. Subjects will attend for 4 visits to the EEC on successive days. Following the last EEC visit a follow-up visit will be performed 3-10 days later.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
170
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total Rhinoconjunctivitis Symptom Score50-54 weeks after the start of treatment in CP005
Secondary Outcome Measures
NameTimeMethod
Total Symptom scores for ocular and nasal symptoms50-54 weeks after the start of treatment in CP005

Trial Locations

Locations (1)

Cetero Research

🇨🇦

Mississauga, Ontario, Canada

Cetero Research
🇨🇦Mississauga, Ontario, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.